Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Average Target Price from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $16.88.

Several brokerages have issued reports on FOLD. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Guggenheim boosted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Large investors have recently made changes to their positions in the business. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics during the third quarter worth $26,000. Hazlett Burt & Watson Inc. increased its position in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,569 shares during the period. Blue Trust Inc. increased its position in shares of Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,831 shares during the period. Arcadia Investment Management Corp MI acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $32,000. Finally, Covestor Ltd increased its position in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 2,312 shares during the period.

Amicus Therapeutics Stock Up 0.9 %

Shares of NASDAQ:FOLD opened at $9.64 on Friday. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.03. The business has a 50 day simple moving average of $9.60 and a two-hundred day simple moving average of $10.43. The firm has a market capitalization of $2.88 billion, a PE ratio of -28.35, a price-to-earnings-growth ratio of 1.69 and a beta of 0.61. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.